Document is current
Any future updates will be listed below
-
Authors
Silverberg, Sarah L.
Shulha, Hennady P.
McMillan, Brynn
He, Guanyuhui
Lee, Amy
Márquez, Ana Citlali
Bartlett, Sofia R.
Gill, Vivek
Abu-Raya, Bahaa
Bettinger, Julie A.
Cabrera, Adriana
Coombs, Daniel
Gantt, Soren
Goldfarb, David M.
Sauvé, Laura
Krajden, Mel
Morshed, Muhammad
Sekirov, Inna
Jassem, Agatha N.
Sadarangani, Manish
-
Funding
Funding for this research was provided by:
Canadian Immunization Research Network
Michael Smith Health Research BC (COV-2020-1033)
Public Health Agency of Canada (2021-HQ-000079)
BC Children’s Hospital Foundation
- License Information
-
More Information
Article History
Received: 8 October 2023
Accepted: 24 December 2023
First Online: 15 January 2024
Declarations
:
: Ethics approval was obtained from the University of British Columbia Children’s and Women’s Research Ethics Board (H20-01886-A011). Informed consent (and assent as appropriate) was obtained from all participants and/or parent or legal guardian.
: not applicable.
: MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo, and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. SG has received research support and/or consulting fees from GlaxoSmithKline, Merck, Moderna, Pfizer, VBI Vaccines, Curevo Vaccine and Altona Diagnostics. BA received honoraria for participation in live meetings from Sanofi Pasteur France and Canada related to pertussis and RSV. Other authors have no competing interests to disclose.
